Skip to content
Triangle logo TriangleGet started
← Study library

NCT02624388 · REGISTRY CONDITION SEARCH

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2024-05-06

Toxicities related to pediatric cancer treatment can lead to significant illness, organ damage, treatment delays, increased health care cost, and decrease in quality of life. Such toxicities are largely due to tissue damage sustained by chemotherapy, and strategies designed to limit such cellular damage to normal tissues may reduce therapy-related morbidity and mortality. In addition to their in vitro and in vivo anti-cancer effects, naturally occurring soy isoflavones have anti-inflammatory and anti-oxidant properties, and have been shown to reduce side effects of therapy in adult oncology clinical trials. This study will examine the effect of genistein, the major isoflavone component in soybeans and the most extensively studied of the soy isoflavones, on short-term side effects of myelosuppressive chemotherapy in pediatric cancer patients. Subjects will be randomized to receive either: a) 30 mg genistein daily throughout chemotherapy Cycles 1 and 2 and placebo during chemotherapy Cycles 3 and 4; or b) placebo daily during chemotherapy Cycles 1 and 2 and 30 mg genistein daily during chemotherapy Cycles 3 and 4. Investigators hypothesize that subjects will have fewer short-term therapy-related side effects during cycles of chemotherapy given in conjunction with genistein supplementation than cycles given with placebo.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Time to Neutrophil Count Recovery Following Myelosuppressive Chemotherapy

→

outcome · POSTED

Serum Marker Levels of Inflammation Erythrocyte Sedimentation Rate (ESR; mm/hr) During Cycles of Chemotherapy

→

outcome · POSTED

Number of Days That Participants Experience Adverse Events That Are Commonly Caused by Chemotherapy Treatment

→

outcome · POSTED

Number of Participants Who Experience Adverse Events That Are Commonly Caused by Chemotherapy Treatment

→

outcome · POSTED

Severity of Adverse Events That Are Commonly Caused by Chemotherapy Treatment Based on CTCAE Severity Criteria

→

outcome · POSTED

Number of Days That Participants Are Hospitalized or Have Prolonged Hospitalization Due to an Adverse Event

→

outcome · POSTED

Number of Days That Planned Cancer Treatment is Delayed Due to an Adverse Event

→

outcome · POSTED

Percentage of Participants Requiring Reduced Treatment Doses Due to an Adverse Event

→

outcome · POSTED

Number of Days That Antimicrobial Treatment is Administered

→

outcome · POSTED

Number of Cycles Where Granulocyte-colony Stimulating Factor (G-CSF) is Administered

→

outcome · POSTED

Number of Times That a Blood Product is Administered for Anemia, Decreased Platelets, Abnormal Bleeding, or the Subject's Best Interest

→

outcome · POSTED

Serum Marker Levels of Inflammation C-reactive Protein (CRP; mg/dL) During Cycles of Chemotherapy

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria 1. Newly diagnosed solid tumor or lymphoma with histological verification 2. Age 1 - 21 years at time of diagnosis 3. Karnofsky/Lanksy performance score of ≥ 50 4. Able to tolerate enteral medication administration 5. Planned chemotherapeutic regimen for a patient must meet all of the following criteria: * A known myelosuppressive regimen which includes at least two of the following agents: actinomycin, carboplatin, cisplatin, cyclophosphamide, daunorubicin, doxorubicin, etoposide, ifosfamide, topotecan * At least four consecutive cycles * Cycle length is either 14 or 21 days * Regimen must either alternate myelosuppressive chemotherapeutic agents in an X-Y-X-Y format, such that the same chemotherapy is given every other cycle (e.g. vincristine/doxorubicin/cyclophosphamide │ ifosfamide/etoposide), or repeat the same chemotherapeutic agents each cycle in an X-X-X-X format (e.g. repeated cycles of cisplatin/etoposide/bleomycin). Courses eligible for this trial may occur at any time during treatment provided that they are consecutive and follow the one of the described patterns. Non-myelosuppressive anti-neoplastic treatments will not be considered for the purposes of determining eligibility. Questions regarding whether or not a patient's chemotherapy plan meets inclusion criteria will be decided by the Study Chair. 6. Informed consent or parental permission and assent obtained prior to trial-related activities 7. Able and willing to comply with all study related procedures 8. Women of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately Exclusion Criteria 1. Known allergy to soy or any soy-based food or supplement 2. Unable or unwilling to discontinue consuming prohibited soy-based food or supplements while participating in this study 3. Pre-existing neutropenia or neutrophil qualitative or quantitative disorder 4. Pre-existing cytopenia or bone marrow failure syndrome 5. History of gastric or duodenal ulcers or hyperacidity syndromes 6. History of Human Immunodeficiency Virus (HIV) 7. Has an active infection requiring systemic therapy 8. Planned treatment does not include myelosuppressive chemotherapy 9. Enrolled on a therapeutic or supportive care clinical trial within the last 30 days 10. Current acute or chronic leukemia diagnosis 11. Requires medication dosing via an enteral feeding tube that terminates in the duodenum or jejunum. (Enteral feeding tubes that terminate in the stomach are acceptable for study medication delivery.) 12. Pregnant or breastfeeding woman 13. Incarceration 14. Secondary malignancy, i.e. the cancer for which the patient is presently or will be receiving treatment may not be a malignancy related to prior cancer therapy 15. Any condition which might be worsened by estrogen, such as breast cancer, uterine cancer, ovarian cancer, endometriosis or uterine fibroids 16. Any condition, in the investigator's opinion, that would compromise patient safety or study outcomes 17. Anyone who, in the investigator's discretion, would be unwilling or unable to comply with study procedures
healthy Volunteers
false
maximum Age
21 Years
minimum Age
1 Year
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4
    intervention Names
    1. Drug: Genistein
    2. Drug: Placebo
    label
    Arm A: Genistein followed by Placebo
    type
    EXPERIMENTAL
  2. description
    Placebo daily throughout chemotherapy cycles 1 and 2, and genistein daily during chemotherapy cycles 3 and 4
    intervention Names
    1. Drug: Genistein
    2. Drug: Placebo
    label
    Arm B: Placebo followed by Genistein
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm A: Genistein followed by Placebo
    2. Arm B: Placebo followed by Genistein
    description
    Estrogen-like compound (isoflavone) derived from soybeans
    name
    Genistein
    other Names
    1. 5, 7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
    2. i-cool tablets containing 30 mg geniVida™
    type
    DRUG
  2. arm Group Labels
    1. Arm A: Genistein followed by Placebo
    2. Arm B: Placebo followed by Genistein
    description
    Pill that contains no medicine
    name
    Placebo
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
CROSSOVER
masking Info
masking
TRIPLE
who Masked
  1. PARTICIPANT
  2. CARE_PROVIDER
  3. INVESTIGATOR
primary Purpose
SUPPORTIVE_CARE
Enrollment
count
4
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Time to Neutrophil Count Recovery Following Myelosuppressive Chemotherapy
    time Frame
    From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays
secondary Outcomes
  1. measure
    Serum Marker Levels of Inflammation Erythrocyte Sedimentation Rate (ESR; mm/hr) During Cycles of Chemotherapy
    time Frame
    Once before treatment starts and then four more times while the study drug is being taken, an 8 - 16 week period if there are no chemotherapy delays
  2. description
    This includes hearing loss/tinnitus, motor neuropathy, oral mucositis
    measure
    Number of Days That Participants Experience Adverse Events That Are Commonly Caused by Chemotherapy Treatment
    time Frame
    From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays
  3. description
    This includes hearing loss/tinnitus, motor neuropathy, oral mucositis
    measure
    Number of Participants Who Experience Adverse Events That Are Commonly Caused by Chemotherapy Treatment
    time Frame
    From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays
  4. description
    This includes hearing loss/tinnitus, motor neuropathy, oral mucositis
    measure
    Severity of Adverse Events That Are Commonly Caused by Chemotherapy Treatment Based on CTCAE Severity Criteria
    time Frame
    From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays
  5. measure
    Number of Days That Participants Are Hospitalized or Have Prolonged Hospitalization Due to an Adverse Event
    time Frame
    From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays
  6. measure
    Number of Days That Planned Cancer Treatment is Delayed Due to an Adverse Event
    time Frame
    From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays
  7. measure
    Percentage of Participants Requiring Reduced Treatment Doses Due to an Adverse Event
    time Frame
    From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays
  8. measure
    Number of Days That Antimicrobial Treatment is Administered
    time Frame
    From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays
  9. measure
    Number of Cycles Where Granulocyte-colony Stimulating Factor (G-CSF) is Administered
    time Frame
    From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays
  10. measure
    Number of Times That a Blood Product is Administered for Anemia, Decreased Platelets, Abnormal Bleeding, or the Subject's Best Interest
    time Frame
    From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays
  11. measure
    Serum Marker Levels of Inflammation C-reactive Protein (CRP; mg/dL) During Cycles of Chemotherapy
    time Frame
    Once before treatment starts and then four more times while the study drug is being taken, an 8 - 16 week period if there are no chemotherapy delays
Full study description
brief Summary
Toxicities related to pediatric cancer treatment can lead to significant illness, organ damage, treatment delays, increased health care cost, and decrease in quality of life. Such toxicities are largely due to tissue damage sustained by chemotherapy, and strategies designed to limit such cellular damage to normal tissues may reduce therapy-related morbidity and mortality. In addition to their in vitro and in vivo anti-cancer effects, naturally occurring soy isoflavones have anti-inflammatory and anti-oxidant properties, and have been shown to reduce side effects of therapy in adult oncology clinical trials. This study will examine the effect of genistein, the major isoflavone component in soybeans and the most extensively studied of the soy isoflavones, on short-term side effects of myelosuppressive chemotherapy in pediatric cancer patients. Subjects will be randomized to receive either: a) 30 mg genistein daily throughout chemotherapy Cycles 1 and 2 and placebo during chemotherapy Cycles 3 and 4; or b) placebo daily during chemotherapy Cycles 1 and 2 and 30 mg genistein daily during chemotherapy Cycles 3 and 4. Investigators hypothesize that subjects will have fewer short-term therapy-related side effects during cycles of chemotherapy given in conjunction with genistein supplementation than cycles given with placebo.
detailed Description
This is a multi-center, randomized, double blind, placebo-controlled crossover study to evaluate the effect of soy isoflavones on the short term untoward effects of myelosuppressive chemotherapy used to treat pediatric cancers. Newly diagnosed cancer patients aged 1-21 years will be registered to the study and informed consent will be obtained prior to any study-related procedures. Stratification will be based on length of chemotherapy cycles, between 14 day and 21 day cycles. Within strata registered subjects will be randomized 1:1 to one of two schedules: Arm A: Subjects will receive genistein daily throughout chemotherapy cycles 1 and 2, and placebo during chemotherapy cycles 3 and 4 Arm B: Subjects will receive placebo daily throughout chemotherapy cycles 1 and 2, and genistein during chemotherapy cycles 3 and 4 Subjects will be assessed for safety and efficacy during each cycle with clinical labs, cytokine panels, and physical exams. Drug compliance will be monitored by use of a patient diary as well as monitoring of serum genistein levels. Adverse events will be monitored starting on Cycle 1 Day 1 through 30 days following the last day of protocol therapy (genistein/placebo).
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-4c5e8f3c45c714acaf99
      requested nct id
      NCT02624388
      primary nct id
      NCT02624388
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      0f0b1d47d700cf556d6212d53b7849c30874e411dbc1a4cfc2cbeef7e5d70ca8
      payload sha256
      b94f395e53fcddf062fe6441d28045ec6ee23a44e0ae71e60ead525ce8f83628
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-4c5e8f3c45c714acaf99
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02624388
      occurrences
      1. context exact
        NCT02624388
        end
        11
        exact text
        NCT02624388
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Kidney Tumors
      query disease state id
      ds-childhood-kidney-tumors
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-kidney-tumors-000.json
      source file sha256
      0f0b1d47d700cf556d6212d53b7849c30874e411dbc1a4cfc2cbeef7e5d70ca8
      source json pointer
      /studies/0/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      9c78b2ce858128df7bd431587532d33a852087ac22c0c1556438cac6aa76b899

    Preserved source evidence · Not medical advice